Medications

JAK1 inhibitors are an established therapeutic pathway in IBD; new, more selective small molecules could expand future treatment options. This study reports a novel compound with strong preclinical activity against...

The study presents a mitochondria-targeted compound that reduced necrosis markers, HMGB1, and IL-1β in cell and mouse colitis models, highlighting a potential new pathway for IBD treatment research.

People with IBD who’ve had organ transplants (or are concerned about infection risk from systemic immunosuppression) may be interested because vedolizumab’s gut‑selective action could be preferable after kidney...

Patients, families, and clinicians may care because the study shows pediatric-onset IBD is more often Crohn's and that children begin advanced therapies earlier than adults. The adult persistence data for vedolizumab and...

The study describes new small molecules that target IL‑6 and NF‑κB and showed anti-inflammatory effects in laboratory and mouse colitis models, signaling a potential early-stage drug-discovery direction relevant to IBD...

The study highlights higher risks of tuberculosis and depression/anxiety associated with advanced therapies—especially anti-TNF agents—which are relevant safety concerns for people with IBD and their care teams. It may...

People using upadacitinib for Crohn’s disease or ulcerative colitis should be aware of a newly reported, reversible semen discoloration that may be dose-related. This could be concerning for patients and affect...

People with ulcerative colitis who have had colectomy can rarely develop inflammation of the small intestine and high-output stomas that are hard to control.

People with IBD who also have bleeding disorders face special risks during endoscopy, surgery, and when using immunosuppressive drugs. This case shows that coordinated care and hemostatic support can allow diagnosis and...

Cure8 could only read part of this source from tradingview.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Inflammatory bowel disease, Crohn's disease, and Research and clinical...

If validated, a blood biomarker (LRG) could help predict which people with Crohn’s disease are more likely to achieve remission and which biologic might be sustained over a year, informing treatment planning and...

This trial tests whether raising the upadacitinib dose to 45 mg can recapture clinical response in people with ulcerative colitis who lost response on the 30 mg maintenance dose. If effective and safe, the approach could...

This trial tests palmitoylethanolamide (PEA), a commercially available supplement with anti-inflammatory actions, as an add-on treatment for mild-to-moderate ulcerative colitis.

GI perforation is a serious, potentially life-threatening complication that can occur in people with autoimmune diseases; this report highlights that perforation can happen during corticosteroid tapering and that careful...

Lower hospitalization rates suggest upadacitinib may reduce severe disease events that require inpatient care, which matters to patients and clinicians aiming to avoid hospital stays and complications. Large real-world...

People with IBD commonly have musculoskeletal pain and need safe short-term pain options. This review suggests selective COX-2 inhibitors may be an option for selected patients in remission when monitored closely, but...

Prednisone is a commonly used steroid for short-term control of IBD flares; changes or reaffirmations in its FDA label affect prescribing and safety guidance that patients and clinicians rely on.

Based on the title and source metadata, this appears to be an opinion or commentary related to Crohn's disease, Inflammatory bowel disease, and Risankizumab. The original article is from Alimentary pharmacology &...

The study suggests that being symptom-free doesn’t guarantee the gut’s microbiome, metabolome, or epithelial functions have returned to a healthy state. Diet—especially ultraprocessed-food intake—was linked to persistent...

The work targets oxidative/nitrosative stress and mucosal repair—mechanisms important in IBD—using a novel delivery vehicle that pairs an approved anti-inflammatory drug with catalytic cerium ions. If translated, this...

The study suggests upadacitinib may improve both symptoms and MRI‑documented healing of perianal fistulas in Crohn’s disease, offering a potential treatment option especially for patients who have not previously received...

This FDA label update adds or confirms ABRILADA (an adalimumab product) as an approved TNF-blocker option for Crohn’s disease (including children ≥6) and ulcerative colitis (adults). It emphasizes infection and...

The label confirms adalimumab is approved for Crohn’s disease and ulcerative colitis and includes boxed safety warnings—information that directly affects patients considering or taking this TNF‑blocking biologic.

This is an FDA drug-label record for ustekinumab that lists approved uses for Crohn’s disease and ulcerative colitis and highlights safety precautions (infections, TB screening, malignancy risk, and vaccine...

Based on the title and source metadata, this appears to be a regulatory update related to Ustekinumab, IL-12/23 inhibitor, and Medications. The original article is from DailyMed.

Based on the title and source metadata, this appears to be a regulatory update related to Tofacitinib, JAK inhibitor, and Medications. The original article is from DailyMed.

An FDA label update names risankizumab (SKYRIZI) as a treatment option for adults with moderately to severely active Crohn’s disease and ulcerative colitis and highlights new or emphasized safety monitoring (liver tests,...

Children with Crohn’s disease have fewer FDA‑approved advanced treatment options than adults, so clinicians and families often must choose among off‑label therapies with limited pediatric evidence.

The FDA label update for tofacitinib lists ulcerative colitis among approved uses and highlights serious safety warnings that are directly relevant to people with IBD considering or taking this oral JAK inhibitor.

This is the FDA DailyMed label for dexamethasone, which lists gastrointestinal uses including short-term use in ulcerative colitis and regional enteritis (Crohn's disease). Patients with IBD may be prescribed...

This is an FDA label entry for YUFLYMA (an adalimumab product) that confirms Crohn’s disease and ulcerative colitis are listed indications and reiterates serious-infection and malignancy warnings for TNF blockers....

The study could create a human-derived lab model to better understand and treat colitis caused by cancer immunotherapy, and to evaluate IBD drugs for that purpose without compromising tumor control.

Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Medications. The original article is from Therapy.

This study examines a combination of ustekinumab plus low‑dose upadacitinib for patients with refractory Crohn’s disease — a group with limited options after failing anti‑TNF and single‑agent therapy. Results could...

This trial is testing an investigational anti-TL1A antibody (tulisokibart/MK-7240) as a potential new treatment for moderate to severe Crohn's disease. Results could affect future treatment options if the drug proves...

A successful Phase 3 trial could provide a new treatment option specifically studied in children with moderate‑to‑severe Crohn's disease, addressing a pediatric population often underrepresented in trials.

The trial is testing risankizumab alone and in combination with investigational ABBV antibodies for moderate-to-severe Crohn’s disease and ulcerative colitis — findings could inform future treatment choices and...

Intestinal fibrosis causes strictures that can lead to obstruction and often require surgery; current drugs mainly reduce inflammation and do not reliably prevent or reverse fibrosis. Advances in understanding fibrosis...

Based on the title and source metadata, this appears to be a case report related to Crohn's disease, Upadacitinib, and JAK inhibitor. The original article is from JAAD case reports.

The study is comparing common biologics given after Crohn's surgery to prevent endoscopic recurrence—a key issue for people who have had bowel resection. Knowing which drugs perform better in real‑world practice could...

This study describes a new oral immunoproteasome inhibitor (ent-F10) with preclinical activity in animal models of ulcerative colitis and rheumatoid arthritis, highlighting a potential new drug-development direction that...

This study reports real-world data on mirikizumab in adults with ulcerative colitis, focusing on clinical and endoscopic remission and inflammatory markers — outcomes patients and clinicians use to judge treatment...

Mucosal healing is an important treatment goal linked to better long-term outcomes, and current anti-TNF therapies achieve mucosal healing in a minority of patients. If adding CDED improves healing, it could offer a...

Adding structured partial enteral nutrition to advanced drug therapy could offer a non-pharmacologic way to improve short-term, steroid-free remission rates in active Crohn's disease if the trial shows benefit.

an investigational oral drug (PALI-2108) being developed specifically for UC and Crohn’s disease, reporting favorable Phase 1 safety and early activity and noting upcoming Phase 2 readouts. For people following new...

This trial directly tests common clinical strategies for managing loss of response to ustekinumab in Crohn’s disease. The findings may change whether doctors routinely escalate to 4-weekly dosing after an IV reinduction,...

Many people with Crohn's also have obesity or diabetes and may be prescribed GLP-1 drugs. Understanding safety, symptom overlap, and current research helps you and your care team make informed choices about starting or...

New approvals and pipeline activity can expand future treatment options and affect availability, pricing, and research priorities for Crohn’s disease. Market analyses can signal which therapies companies expect to...